Thrombolysis is well established as effective therapy in AMI. Two thrombolytic agents, streptokinase and tissue plasminogen activator (tPA), are now widely available for clinical use. These agents have different effects, and there has been considerable debate as to which is superior. Both are effective in preserving myocardial function and reducing mortality. However, the confidence limits of these findings overlap, and no firm conclusions can be made from comparing trials enrolling different populations with different baseline characteristics and ancillary treatments such as angioplasty. There have been few "head-to-head" comparisons. These trials show that tPA achieves better lysis rates than streptokinase, but the theoretic advantage of fibrin specificity does not result in fewer adverse effects or greater preservation of LV function. Although each drug may have specific indications, the drugs appear similar in clinical benefit, and further comparison trials are required.

Influenza A results in considerable morbidity, mortality and economic costs. Although immunoprophylaxis and chemoprophylaxis are targeted toward high-risk groups, persons with human immunodeficiency virus (HIV) infection have not been widely recognized as being at increased risk of influenza infection. We report a case of influenza A pneumonitis in a patient infected with HIV. The literature on influenza immunization of HIV-infected patients is reviewed and the implications for public health are discussed. Consideration should be given to influenza immunization and chemoprophylaxis in this enlarging population. Further investigation of the pathogenesis and epidemiology of influenza in HIV-infected patients is warranted.

Physicians increasingly are being called upon to make difficult decisions about intensive care for patients with the acquired immunodeficiency syndrome (AIDS). AIDS patients who require intensive care have a poor prognosis; the in-hospital mortality rate of those receiving mechanical ventilation for P carinii pneumonia is 86-100 percent in most studies. However, in the past year, two studies documenting improved outcome have been published. Physicians should understand these outcome data and use well-established ethical principles to allow informed competent patients with AIDS to express their preferences regarding intensive care. Patients should be encouraged to provide advanced directives regarding life-sustaining treatments or to designate surrogate decision-makers to be consulted should they lose mental competence. The health care system should provide alternatives to the ICU for compassionate terminal care. However, arbitrary policies denying intensive care to AIDS patients for whom it is medically indicated and desired are not warranted.

Among 72 patients with Behçet's syndrome, seven had pulmonary vascular involvement. Additional data from 42 cases in the literature are discussed. Recurrent episodes of dyspnea, cough, chest pain, and hemoptysis were the primary clinical signs, mainly in young men, appearing 3.6 years after the first manifestation of Behçet's syndrome. Fever, elevated ESR, and anemia were common, and chest x-ray films showed pulmonary infiltrates, pleural effusions, and prominent pulmonary arteries. Ventilation-perfusion scans showed perfusion defects even when chest x-ray films were normal. Pulmonary artery aneurysms were seen in 7/13 in whom angiography was done. Of 42 patients, 16 died, 15 from fatal pulmonary hemorrhage, 80 percent within two years from the development of pulmonary disease. Histopathologic study results showed vasculitis of pulmonary vessels of various sizes, leading to thrombosis, destruction of the elastic laminae, aneurysms, and arteriobronchial fistula. In addition, pulmonary emboli and the aphthous lesion of the tracheobronchial tree may aid the clinical picture. Anticoagulant therapy may be hazardous in patients with aneurysmal dilatation of the pulmonary vascular tree, and the beneficial effect of corticosteroid therapy is discussed. Pulmonary vasculitis in Behçet's syndrome is a unique clinical and pathologic picture, differing from other vasculitides affecting the lung, presents a major threat to the patient's life.